RecruitingNot ApplicableNCT05430178

Metabolic Pathology of Pediatric NAFLD

Understanding the Metabolic Pathology of Pediatric Obesity and NAFLD


Sponsor

University of Oklahoma

Enrollment

100 participants

Start Date

May 25, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Nonalcoholic fatty liver disease (NAFLD) is now the most common liver disease worldwide and affects nearly 40% of obese youth and up to 10% of the general pediatric population. Some features of NAFLD are similar in children and adults, yet fibrosis and inflammation are more common in the portal zone and occur earlier in pediatric NAFLD patients than adults. This portends a rapid progression to end-stage liver disease in early adulthood. For the majority of children with NAFLD, mechanisms driving the origin and rapid progression of disease remain unknown. Thus, there is a critical, unmet need to study the specific underlying patterns of metabolic and molecular changes in the liver underlying the development and progression unique to children with NAFLD. This proposal will test the hypotheses that children with NAFLD have excess glucose and lipid produced by the liver, that those events are regulated by specific variations in the amount and location of RNAs and proteins in liver, and that the concentration of specific micro-RNAs in the blood can be used as a biomarker for NAFLD in pediatric patients.


Eligibility

Min Age: 10 YearsMax Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying De novo lipogenesis test, Gluconeogenesis test, and others for people with nonalcoholic fatty liver, nonalcoholic steatohepatitis, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHEROral sugar tolerance test

Measurement of glucose and insulin for calculation of insulin sensitivity

OTHERDe novo lipogenesis test

Oral consumption of deuterated water to measure incorporation of label into lipids

OTHERGluconeogenesis test

Oral consumption of 13C-labeled glycerol to measure incorporation into glucose


Locations(1)

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05430178


Related Trials